Sunday, May 5, 2024
Home Client Page 23

Client

    Random
    Citius, Biotech Stock Review

    Adding Citius Pharma (CTXR) $1.29 to the 2021 Biotech Portfolio.

    Client Editor / Curator -
    The 2021 Biotech Six Pack, Six Stocks We Expect to Double. We're still putting the 2021 list together now,...

    Revive Therapeutics (RVVTF) Enters the Danger Zone.

    Client Editor / Curator -
    What Danger You Ask? Danger #1, the FDA doesn't like the data, and you own the stock.
    Immunomedics IMMU, Biotech Stock Review

    Immunomedics (IMMU) up 100% Today or $2 Billion in Value.

    Client Editor / Curator -
    Again as mentioned a few weeks ago, our bearish market opinion is related to large-caps and large-cap funds and ETF's. If...
    Aphex BioCleanse

    Aphex BioCleanse Systems. Our Favorite CoronaVirus Story.

    Superbug News - CoronaVirus Watch List Editor / Curator -
    Former Eastman Kodak Scientist and Engineers Develop Liquid Germ Killer Hy-IQ® to Revolutionize the way Deadly Bacteria and Virus are Eradicated
    Silo Pharma, Psychedelic Stock Review, Roland Rick Perry

    SILO Pharma (SILO) Gains 53%

    Client Editor / Curator -
    For Now, Volatility Remains and the Traders, Seem to be Having the Most Fun. Silo Pharma Gains 53%...

    LQR House Inc. Announces Pricing of $11 Million Public Offering

    Internet News Editor / Curator -
    MIAMI BEACH, FL / ACCESSWIRE / November 10, 2023 / LQR House Inc. (the "Company" or "LQR House") (NASDAQ:LQR), today announced the...
    Dalarada Health, Biotech Stock Review

    Dalrada Cervical Cancer Testing Kit Study.

    Client Editor / Curator -
    KEY TAKEAWAYS Dalrada Corp (DFCO) LIVE QUOTE

    Ardelyx (ARDX) $3.40, Receives FDA Approval.

    Client Editor / Curator -
    BooYah, Ardelyx shoots and we score (again) last week..but wait, there's more! It trades down post-approval as short-term...

    Dennis Nguyen, Founder/Chairman/CEO of Nasdaq-listed Society Pass Inc. (Nasdaq: SOPA) to Speak at NXT...

    Internet News Editor / Curator -
    SINGAPORE, Feb. 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Society Pass Incorporated ("SoPa”) ( Nasdaq: SOPA ), Southeast Asia’s (SEA) next generation, data-driven, loyalty, fintech and e-commerce...

    Interviews With Dr. Don Diamond, Lead Developer in the GeoVax (GOVX) Vaccine for Leukemia...

    Client Editor / Curator -
    Dr. Don Diamond has stated, "The City of Hope is excited to license this vaccine to GeoVax (GOVX) to progress to large-scale...
    1...222324...36Page 23 of 36

    Latest article

    We’re in Tampa for the Kentucky Derby.

    Client Editor / Curator -
    GeoVax (GOVX), Sees a Little Volume. Normally, we get a little nervous when one of the companies we...

    Institutional Analyst Newsletter. Citius (CTXR), GeoVax (GOVX.

    Institutional Analyst Newsletter Editor / Curator -
    DERBY WEEKEND - WE'RE HEADED TO TAMPA!HAT'S ON, DRINK'S UPADDING CITIUS PHARMA (CTXR) $0.66, TO WATCHLISTUPDATING GEOVAX LABS (GOVX) $1.43OUR $26...

    Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.

    Client Editor / Curator -
    Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!
    The Internet Stock Review is one of Wall Streets oldest newsletters covering internet technology having launched in 1999. The Biotech Stock Review is rather old too, having launched in 2002. We make our money by purchasing stock with our services, so the better our client stocks do, the better we all do. And when we're wrong, we feel the pain too! See our research reports for important disclaimer details. Content is provided by Institutional Analyst Inc., the website is managed by Revelers.IO Media Group Inc. To see if your Company qualifies for coverage, call 310-594-8062
    Contact us: [email protected]
    © Managed by Revelers.IO Media Group Inc.